Kabra Drugs (524322)
FAST GROWERScore breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹8.3 |
| Market Cap | ₹72.36 Cr |
| P/E Ratio | 16.83 |
| ROCE | -7.82% |
| ROE | 131% |
| Dividend Yield | 0% |
| Profit Growth | 575.93% |
| Debt/Equity | — |
| Sales Growth | 0% |
| 52-Week Range | ₹12.21 — ₹35.52 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹1.38 |
Kabra Drugs trades with a P/E ratio of 16.83, ROCE of -7.82%, ROE of 131%, profit growth of 575.93%.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer